| Keywords: |
vasculotropin; intercellular signaling peptides and proteins; vascular endothelial growth factor a; unclassified drug; clinical trial; dose response; drug efficacy; nonhuman; pyridines; drug approval; nausea; myalgia; administration, topical; drug potency; backache; syncope; europe; hypotension; sexual dysfunction; drug mechanism; drug therapy, combination; enzyme inhibitors; prostaglandin; short survey; headache; hot flush; corpus cavernosum; gastroesophageal reflux; erectile dysfunction; visual disorder; phosphodiesterase v inhibitor; prostaglandin e1; sildenafil; tadalafil; vardenafil; sexual intercourse; phosphodiesterase inhibitors; impotence; libido; tachycardia; drug use; nitric oxide synthase; penis erection; amides; alpha adrenergic receptor blocking agent; vertigo; dopamine receptor; sweating; vasoactive intestinal polypeptide; oxytocin; self injection; drug marketing; vascular endothelial growth factors; nose congestion; alprostadil; endothelial growth factors; phosphodiesterase inhibitor; dopamine receptor stimulating agent; smooth muscle relaxation; adrenergic alpha-antagonists; 4 (1 aminoethyl) n (4 pyridyl)cyclohexanecarboxamide; calcium channels; hormone receptor stimulating agent; humans; human; male; priority journal; dopamine agonists; apomorphine; lymphokines; 1 (2 hydroxy 5 trifluoromethylphenyl) 5 trifluoromethyl 2(3h) benzimidazolone; 3 [3 [4 [4 fluoro 2 (2,2,2 trifluoroethoxy)phenyl] 1 piperazinyl]propyl] 5 methyl 1h pyrimidine 2,4 dione; abt 724; invicorp; melanocortin receptor; melanotan ii; n acetylnorleucylaspartylhistidyl dextro phenylalanylarginyltryptophyllysine 2,7 cyclic amide; phentolamine mesylate; pinacidil; potassium channel stimulating agent; prostavasin; receptors, corticotropin; receptors, melanocortin
|
